When Jubilant Ingrevia was carved out of Jubilant Life Sciences in February 2021, it inherited something most demerged entities never get: a four-decade head start. The company is one of the world’s largest manufacturers of pyridine and its derivatives — a family of nitrogen-containing compounds that sit at the heart of pharmaceuticals, agrochemicals, and animal nutrition. That inheritance came with 1,500 customers, operations spanning more than fifty countries, and the quiet confidence of a business that had been profitable long before it had its own stock ticker.
Pyridine is not a household name. It is a six-membered aromatic ring with one nitrogen atom, and most people will go their entire lives without thinking about it. But pyridine and its derivatives are everywhere: in the vitamin B3 (niacin) that fortifies breakfast cereal, in the herbicides that protect rice paddies across Asia, in the anti-tuberculosis drugs that the World Health Organisation distributes in sub-Saharan Africa. If you have ever taken a prescription medicine, there is a reasonable chance that a pyridine derivative was involved somewhere in its synthesis.
Jubilant Ingrevia understood this before most of the industry did. The Jubilant Bhartia Group began manufacturing pyridine in the 1980s, at a time when global supply was dominated by a handful of European and Japanese producers. By investing in backward integration — making pyridine from basic raw materials rather than buying it — the company built a cost structure that competitors found difficult to match. Today, Jubilant Ingrevia operates one of the world’s largest single-site pyridine manufacturing complexes, in Gajraula, Uttar Pradesh.
For most of its history, Jubilant Ingrevia was a product company. It made specialty chemicals and sold them in bulk. The customer bought a molecule; the relationship ended at the loading dock. But the global pharmaceutical industry has been moving in a different direction. Innovator companies — the firms that discover new drugs — increasingly want their chemical suppliers to do more than supply. They want partners who can develop a custom synthesis route, scale it up, handle the regulatory filings, and manufacture the finished intermediate under GMP conditions.
This is the CDMO model: Contract Development and Manufacturing Organisation. And Jubilant Ingrevia has been pivoting toward it with intent. The company now offers custom synthesis, process development, and contract manufacturing for pharmaceutical intermediates and active ingredients. It is a transition from selling commodities to selling capabilities — from a business where you compete on price to one where you compete on chemistry, regulatory expertise, and the ability to keep a customer’s proprietary molecule confidential.
The pivot remains underway. Specialty chemicals still account for the majority of revenue. But the trajectory is clear: the company is investing in R&D capacity, adding GMP manufacturing lines, and hiring process chemists. The goal is to become an integrated partner for global pharma companies, not merely a supplier of building blocks.
Jubilant Ingrevia organises its operations into three distinct segments, each serving different end markets but drawing on the same underlying chemistry platform. The strength of the model is that pyridine derivatives flow downstream into all three — giving the company both diversification and vertical integration.
Jubilant Ingrevia serves more than 1,500 customers across sixty-three countries. Its manufacturing footprint is concentrated in India, with major production facilities in Gajraula (Uttar Pradesh), Nanjangud and Nira (Karnataka and Maharashtra), and Bharuch (Gujarat). The Gajraula complex alone houses one of the largest pyridine plants in the world — a scale advantage that allows the company to offer competitive pricing while maintaining the quality standards required by regulated pharmaceutical markets in the US, Europe, and Japan.
The customer base spans multinational pharmaceutical companies, global agrochemical firms, and nutrition ingredient distributors. The company’s products end up in medicines, crop protection formulations, animal feed supplements, and consumer health products across six continents.
Revenue peaked at $594 million in FY22, driven by a post-pandemic surge in chemical prices and strong demand across all three segments. The subsequent normalisation — down to $573 million in FY23 and $497 million in FY24 — reflected the cooling of commodity chemical prices rather than any loss of market position. FY25 revenue of $501 million suggests the trough has passed.
The more important story is the shift in revenue quality. As the CDMO business scales, a growing share of revenue comes from longer-term contracts with higher margins and greater customer stickiness. A customer who buys bulk pyridine can switch suppliers in a quarter. A customer who has co-developed a proprietary synthesis route with Jubilant’s process chemists is unlikely to walk away. That difference — between transactional and relational revenue — is what the company is betting its future on.
Sources: Jubilant Ingrevia Annual Reports FY2020–21 through FY2024–25. US FDA facility registration data.